
- /
- Supported exchanges
- / TO
- / CPH.TO
Cipher Pharmaceuticals Inc (CPH TO) stock market data APIs
Cipher Pharmaceuticals Inc Financial Data Overview
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company's licensed products comprise Absorica, an oral retinoid indicated for the treatment of f severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Lipofen, which is indicated as adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, and to increase HDL-C, as well as to reduce triglycerides in adult patients; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults. Its pipeline products include MOB-015, a topical formulation of terbinafine, which is in phase 3 clinical trial for treatment of onychomycosis; CF-101 (Piclidenoson) that is in phase 3 clinical trial for severe plaque psoriasis and rheumatoid arthritis; and DTR-001, a tattoo removal cream, which is in pre-clinical stage. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Mississauga, Canada.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Cipher Pharmaceuticals Inc data using free add-ons & libraries
Get Cipher Pharmaceuticals Inc Fundamental Data
Cipher Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 26 461 K
- EBITDA: 12 573 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-07
- EPS/Forecast: 0.26
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Cipher Pharmaceuticals Inc News

Cipher Pharmaceuticals Reports Voting Results for the Election of Directors
MISSISSAUGA, Ontario, June 12, 2019 (GLOBE NEWSWIRE) -- Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company"), in accordance with Toronto Stock Exchange requirements, announced today ...


Aclaris Therapeutics Partners with Cipher Pharmaceuticals to seek regulatory approval and commercialize A-101 40% topical solution for the treatment of raised seborrheic keratoses in Canada
The agreement will expand the availability of the first and only U.S. FDA-approved prescription product for the treatment of raised seborrheic keratoses (SKs) WAYNE, Pa., April 06, 2018 (GLOBE NEWS...

The Life Sciences Report Interviews Alan Leong of BioWatch News
SAN FRANCISCO, CA--(Marketwired - January 22, 2016) - Combining academic discipline with methodical due diligence, Alan Leong of BioWatch News undertakes a regimented review of each biotech and medte...

Cipher Pharmaceuticals' Shawn Patrick O'Brien Interviewed by The Life Sciences Report
SAN FRANCISCO, CA--(Marketwired - November 05, 2015) - Skin disorders encompass a broad class of medical indications, from psoriasis to melanoma. Many companies focus on developing treatments for spec...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.